Seres Therapeutics Appoints New Executive Leadership
PUBLIC · MCRBMar 02, 2026
Position
Chief Scientific Officer
Company
Seres Therapeutics
Matthew Henn, Ph.D.
CambridgeBiotechnologyHealth CareTherapeutics
Description
On February 27, 2026, Seres Therapeutics, Inc. announced the appointment of Richard N. Kender as Executive Chair of the Board and Interim Chief Executive Officer
Who to call at Seres Therapeutics, and when
A new leader at Seres Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day Seres Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Seres Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Seres Therapeutics. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Seres Therapeutics
Location
Cambridge, Massachusetts, United States
About
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Seres’ lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiome therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Seres Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CambridgeBiotechnologyHealth CareTherapeutics